Last reviewed · How we verify
Ertapenem intravenous
Ertapenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Ertapenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Complicated intra-abdominal infections, Complicated skin and soft tissue infections, Community-acquired pneumonia.
At a glance
| Generic name | Ertapenem intravenous |
|---|---|
| Sponsor | Bayer |
| Drug class | Carbapenem antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ertapenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall disruption and bacterial death. It has activity against a wide range of gram-positive, gram-negative, and anaerobic bacteria, making it useful for treating complicated intra-abdominal infections, complicated skin infections, and other serious bacterial infections.
Approved indications
- Complicated intra-abdominal infections
- Complicated skin and soft tissue infections
- Community-acquired pneumonia
- Complicated urinary tract infections
- Acute pelvic infections
Common side effects
- Diarrhea
- Nausea
- Headache
- Vomiting
- Phlebitis at injection site
- Seizures
Key clinical trials
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) (PHASE1)
- Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis (PHASE2)
- Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients (PHASE2, PHASE3)
- Ertapenem Administered Subcutaneously Versus Intravenously (PHASE3)
- Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ertapenem intravenous CI brief — competitive landscape report
- Ertapenem intravenous updates RSS · CI watch RSS
- Bayer portfolio CI